ZP-8396

Zealand Pharma CEO Adam Steensberg has indicated that the company's obesity drug candidate petrelintide could reach the market earlier than planned following a strategic partnership with Roche.

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

The first quarter of 2025 witnessed significant biotech partnership activity, with Eli Lilly, AstraZeneca, and Novo Nordisk emerging as top collaborators in deals worth billions across small molecules, antibodies, and RNA therapeutics.

Zealand Pharma has initiated a Phase 2b trial (ZUPREME-1) for petrelintide, a long-acting amylin analog, in overweight or obese individuals.

Zealand Pharma reported positive Phase 1b results for petrelintide and dapiglutide, advancing both into Phase 2b trials for overweight and obese patients.